Active Colorectal Cancer Clinical Trials

Data from ClinicalTrials.gov · Privacy-First Design · No Account Required · No Health Data Stored

Why Consider a Colorectal Cancer Clinical Trial?

• Find Trials That Fit — Browse recruiting Colorectal Cancer trials pulled directly from ClinicalTrials.gov — updated continuously so you always see real, active studies.
• No Medical Jargon — Eligibility criteria are rewritten into plain yes-or-no questions. It's always okay to answer "not sure" — your doctor can help fill in the rest.
• See How Well You Match — Get a clear picture of how closely a trial fits your situation, so you know which ones are worth bringing to your oncologist.
• Ready for Your Appointment — Generate a printable or emailable summary for your next visit. A caregiver can send it to your doctor ahead of time.

How It Works

1. Share a Few Details — Enter your Colorectal Cancer type, stage, and location. No personal health information is required or stored.
2. Answer Yes-or-No Questions — We rewrite complex eligibility criteria into plain language. "Not sure" is always a valid answer.
3. Bring Results to Your Doctor — Get a printable summary with the NCT ID, match assessment, and questions to ask your oncologist.

Free · No account · Nothing you enter is stored

Colorectal Cancer Clinical Trial FAQ

What does MSI-H or mismatch repair deficient (dMMR) mean for clinical trial eligibility?

MSI-H (microsatellite instability-high) or dMMR (mismatch repair deficient) colorectal cancer responds very well to checkpoint immunotherapy, like pembrolizumab. Many immunotherapy trials specifically seek MSI-H/dMMR patients. This is determined by a standard pathology test on your tumor tissue. If you haven't been tested, ask your oncologist — it can significantly expand your trial options.

Are there KRAS or BRAF-targeted trials for colorectal cancer?

Yes. KRAS G12C inhibitors (like sotorasib and adagrasib) and BRAF V600E-targeted combinations (encorafenib + cetuximab) have recently gained FDA approval and are being tested in further trials. Next-generation KRAS inhibitors that target other KRAS mutations (G12D, G12V) are in active clinical trials. Molecular profiling of your tumor is essential to identify which mutations you carry.

Do colorectal cancer trials enroll both colon and rectal cancer patients?

Most do, especially metastatic colorectal cancer trials, which typically enroll both colon and rectal primaries. Some trials — particularly those involving surgical technique or local-regional treatment for rectal cancer — may be specific to rectal cancer. Trialify will reflect these distinctions in the eligibility questions.

Can I join a colorectal cancer trial after my cancer has spread (metastatic)?

Yes. Many trials specifically target metastatic colorectal cancer (mCRC), including first-line, second-line, and later-line settings. There are also trials for early-stage, resectable, and locally advanced colorectal cancer. Trialify lets you filter by disease stage so you see the studies most relevant to where your cancer is.

How do I find a colorectal cancer trial near me?

Enter your location and cancer type on Trialify. We search ClinicalTrials.gov and sort results by distance from your ZIP code. Each trial card shows which sites are recruiting and how far they are from you. Many trials also offer telehealth screening visits, reducing the need for in-person travel.

Explore Other Cancer Trial Guides

• Metastatic Colorectal Cancer — Metastatic colorectal cancer (mCRC) is the most advanced stage, with cancer spread to the liver, lungs, or other organs. Trials are testing KRAS G12C inhibitors, BRAF V600E combinations, MSI-H immunotherapy, antibody-drug conjugates (trastuzumab deruxtecan for HER2+), and novel agents for all molecular subgroups.
• Pancreatic Cancer — Pancreatic cancer trials are at the forefront of KRAS inhibitor research, mRNA vaccines, and combination immunotherapy. Participating in a trial may give access to treatments not yet available to the general public.
• Liver Cancer — Liver cancer trials are studying checkpoint inhibitor combinations, locoregional treatments (TACE, ablation), and novel targeted agents for hepatocellular carcinoma across all disease stages.
• Bladder Cancer — Bladder cancer trials are evaluating checkpoint immunotherapy, enfortumab vedotin-based combinations, and FGFR inhibitors for both non-muscle-invasive and muscle-invasive disease.